Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14066119 | 1.00 | CYP3A4 (0.35) | CYP3A4ALOX15OPRM1OPRL1MCL1 | |
| SCHEMBL4860492 | 0.76 | LMNA (0.36) | CYP3A4ALOX15LMNA | |
| SCHEMBL4860473 | 0.76 | LMNA (0.36) | CYP3A4ALOX15LMNA | |
| SCHEMBL4860482 | 0.76 | LMNA (0.36) | CYP3A4ALOX15LMNA | |
| SCHEMBL14066120 | 0.76 | LMNA (0.36) | CYP3A4ALOX15LMNA | |
| SCHEMBL7596531 | 0.74 | LMNA (0.34) | CYP3A4ALOX15LMNA | |
| SCHEMBL425466 | 0.69 | — | — | |
| SCHEMBL13567026 | 0.69 | MCL1 (0.40) | OPRM1OPRL1MCL1LMNAALDH1A1 | |
| Hydrochloric Acid SCHEMBL29494595 | 0.67 | — | — | |
| SCHEMBL17173842 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1666047-A1 | Pharmaceutical compositions comprising nitric oxide-releasing pyrrolidones | The Government of the United States of America As represented by the Secretary of the Department Of Health and Human Services (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-0793500-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITRIC OXIDE-RELEASING POLYSACCHARIDES | US GOV HEALTH & HUMAN SERV (US) | 2006-05-03 | — | — | EP | disclosed |
| US-6379660-B1 | BIOPOLYMERS; ADMINISTERING THERAPY DOSAGE; ANTITUMOR AGENTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2002-04-30 | — | — | US | disclosed |
| US-6200558-B1 | PEPTIDE, POLYPEPTIDE, PROTEIN, OLIGONUCLEOTIDE OR NUCLEIC ACID, TO WHICH IS BOUND A NITRIC OXIDE-RELEASING N2O2-FUNCTIONAL GROUP | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2001-03-13 | — | — | US | disclosed |
| US-5700830-A | Use of nitric oxide-releasing agents for reducing metastasis risk | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-12-23 | — | — | US | disclosed |
| US-5632981-A | Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-05-27 | — | — | US | disclosed |